Antihypertensive Drugs and the Risk of Cancer: A Nationwide Cohort Study

In‐Jeong Cho(Ewha Womans University), Jeong‐Hun Shin(Hanyang University), Mi‐Hyang Jung(Hallym University Dongtan Sacred Heart Hospital), Chae Young Kang(Daegu University), Jinseub Hwang(Daegu University), Chang Hee Kwon(Konkuk University Medical Center), Woohyeun Kim(Hanyang University), Dae‐Hee Kim(Ulsan College), Chan Joo Lee(Yonsei University), Si‐Hyuck Kang(Yonsei University), Ju‐Hee Lee(Chungbuk National University Hospital), Hack‐Lyoung Kim(Seoul National University), Hyue Mee Kim(Seoul National University), Iksung Cho(Ewha Womans University), Hae‐Young Lee(Seoul National University Hospital), Wook‐Jin Chung(Gachon University Gil Medical Center), Sang‐Hyun Ihm(The Catholic University of Korea Bucheon St. Mary's Hospital), Kwang Il Kim(Seoul National University Bundang Hospital), Eun Joo Cho(The Catholic University of Korea Yeouido St. Mary's Hospital), Il Suk Sohn(Kyung Hee University Hospital at Gangdong), Sungha Park(Yonsei University), Jinho Shin(Hanyang University), Sung Kee Ryu(Eulji University), Jang‐Young Kim(Yonsei University), Seok‐Min Kang(Yonsei University), Myeong‐Chan Cho(Chungbuk National University Hospital), Wook Bum Pyun(Ewha Womans University), Ki‐Chul Sung(Kangbuk Samsung Hospital)
Journal of Clinical Medicine
February 15, 2021
10.3390/jcm10040771
Cited by 39Open Access
Full Text

Abstract

We sought to assess the association between common antihypertensive drugs and the risk of incident cancer in treated hypertensive patients. Using the Korean National Health Insurance Service database, the risk of cancer incidence was analyzed in patients with hypertension who were initially free of cancer and used the following antihypertensive drug classes: Angiotensin-converting enzyme inhibitors (ACEIs); angiotensin receptor blockers (ARBs); beta blockers (BBs); calcium channel blockers (CCBs); and diuretics. During a median follow-up of 8.6 years, there were 4513 (6.4%) overall cancer incidences from an initial 70,549 individuals taking antihypertensive drugs. ARB use was associated with a decreased risk for overall cancer in a crude model (hazard ratio (HR): 0.744, 95% confidence interval (CI): 0.696-0.794) and a fully adjusted model (HR: 0.833, 95% CI: 0.775-0.896) compared with individuals not taking ARBs. Other antihypertensive drugs, including ACEIs, CCBs, BBs, and diuretics, did not show significant associations with incident cancer overall. The long-term use of ARBs was significantly associated with a reduced risk of incident cancer over time. The users of common antihypertensive medications were not associated with an increased risk of cancer overall compared to users of other classes of antihypertensive drugs. ARB use was independently associated with a decreased risk of cancer overall compared to other antihypertensive drugs.

Related Papers

A Proportional Hazards Model for the Subdistribution of a Competing Risk
Jason P. Fine, Malcolm H. Ray|Journal of the American Statistical Association|1999|13.5k
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Marc A. Pfeffer, Karl Swedberg, Christopher B. Granger et al.|The Lancet|2003|1.9k
Epidemiology and risk factors for kidney cancer
Wong-Ho Chow, Linda M. Dong, Susan S. Devesa|Nature Reviews Urology|2010|1.4k
The renin–angiotensin system and cancer: old dog, new tricks
Amee J. George, Walter G. Thomas, Ross D. Hannan|Nature reviews. Cancer|2010|525
Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials
İlke Sipahi, Sara M. Debanne, Douglas Y. Rowland et al.|The Lancet Oncology|2010|479